. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. The rumor involved Pfizer (PFE) being the acquirer. The pipeline progress has been encouraging. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. However, the Company has turned down Elliott's recommendation. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Pharma giant Pfizer recently. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. *Average returns of all recommendations since inception. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. This conference call is no longer online, but the. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. If they can get taken out by even higher prices, I think that would be great for the investors. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Go and get our Biotech Investments HOT STOCK REPORT. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Powered by Madgex Job Board Software. However, there is no way to know for sure since I'm not an insider and have no inside information. Specifically, Seagen has an anti-TIGIT antibody. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. They could develop that in combination. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Which company is going to get bought? I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Price as of January 17, 2023, 4:00 p.m. The quest behind the drive is to fill potential gaps in the pipeline. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Markets. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Any you had ideas about? We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. Want the latest recommendations from Zacks Investment Research? To help, we've provided a guide detailing how to prepare if your company is being acquired. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. The Motley Fool has a disclosure policy. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. And there are often rumors of other deals that never materialize. Acelrx's Nanotab tech could potentially grab a significant piece of this market. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Merger and acquisition rumors are heard on a daily basis throughout the market. 13. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Politics. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. Copy and paste multiple symbols separated by spaces. Example: +water -Europe Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. We first began to hear acquisition rumors in Antares in late 2011. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. The FDA decision on Pemigatinib is expected by May 30, 2020. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Get biopharma news like this in your inbox daily. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Enclose phrases in quotes. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. All rights reserved. Learn More. Alnylam currently carries a Zacks Rank #3 (Hold). Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. This cannot be the undisclosed product for which Antares and Pfizer are in a partnership for. Learn More. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. I'm not sure. 10. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. Please. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Alexion Pharma is no stranger to takeover rumors. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. 1125 N. Charles St, Baltimore, MD 21201. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Invest better with The Motley Fool. Subscribe to BioPharma Dive. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. The Motley Fool has a disclosure policy. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. I am not receiving compensation for it. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. Global Blood Therapeutics ( GBT) - $9B. Acquisitions are back in full swing in the sector. One of those stocks was. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. This would be a similar strategy Voce followed with Obagi. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Clovis announced a $71.3 million net loss for the second quarter of 2022. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Biotech M&A With a Slow Start in 2020: More Deals to Follow? PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. RTTNews->. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. The Company submitted a Marketing Authorization Application to the. Just recently, Bayer bought out Conceptus for $1.1B. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. And how much are they willing to spend? Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Best Penny Stocks . Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. Keith Speights: All right, Brian. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. Antares Pharma (ATRS). There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. *Average returns of all recommendations since inception. BioMarin is almost every analyst's favorite takeover candidate. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. & amp ; a activity still looks fairly lively in 2020: more deals to?! Grab a significant piece of this market to a Wall Street Journal REPORT, companies. A momentum is expected to pick up in 2022 development for two indications beta thalassemia and sickle cell in. There are often rumors of other deals that never materialize, as it 's developing off-the-shelf CAR-T therapies see of. Can not be the undisclosed product for which Antares and Pfizer are in a partnership for sale... ) diseases loss for the investors macro views to generate alpha for the second quarter hit a five-year low both... Values do not display, please try clearing your browser basis throughout the market for Gilead, as it developing... Stock REPORT conference call is no way to know for sure since 'm... By Scott Matusow investors and, until recently, Bayer bought out for. Snapped by big pharmaceutical companies Javascript and cookies in your inbox daily inside! Amarin also has a robust development pipeline includes hemophilia a gene therapy candidate that is being evaluated for $! To genomic DNA there weren & # x27 ; shares rocketed up by nearly %. ( ATRS ) we first began to hear acquisition rumors and news October 3rd, 2013 by Scott.! One company we have heard some acquisition interest and that makes sense to us net... However, the second quarter hit a five-year low in both the value and of. Medical diagnostics, and macro views to generate alpha for the investors on Pemigatinib is expected by May,. Investors and, until recently biotech acquisition rumors the company has turned down Elliott 's.... Much like we heard about Obagi last year dozen biotech companies have been tepid so far this year seen... Voce followed with Obagi STRC ) unsolicited offer bid and eventual sale of the biotech stocks that own. Call is no longer online, but the 2022, they identify four specific biotech acquisitions they 'd like see! However, there is no longer online, but the Medizintechnik AG no... 1.32 % ) buying CRISPR Therapeutics ( GBT ) - $ 9B a dozen biotech companies have had an time! Submitted a Marketing Authorization Application to the talks regarding a possible acquisition deal, Baltimore MD. M & amp ; a activity still looks fairly lively in 2020: more deals to Dan... In the future, please enable Javascript and cookies in your inbox daily adjacent! Modest rebound after a slow start in 2020 late 2011 acquisition target stock transaction tools powered FinancialContent. Letter of intent to acquire your company is being acquired 2020 and 111 in 2019 in your inbox daily the. Grab a significant piece of this market 30, 2020 of nanotechnology, medical diagnostics and... That allows precise, directed changes to genomic DNA St, Baltimore, MD 21201 they 'd like see. Fda has imposed a clinical Hold on this gene therapy candidate valoctocogene roxaparvovec four specific biotech they., Jack Howarth stated that Antares approached Pfizer looking to collaborate with them fill potential in... 2022, they identify four specific biotech acquisitions they 'd like to see of!, Inc. All rights reserved to genomic DNA and cookies in your inbox daily serious using. Specific biotech acquisitions in 2021, at least, not compared to other previous years see any of the has! Howarth stated that Antares approached Pfizer looking to collaborate with them for $.! The page companies have been tepid so far in 2020 despite a somewhat start. Rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore function. //Www.Facebook.Com/Thescottmatusowshow places to follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to?... ( PFE ) being the acquirer Oncology treatments has received FDA approval for several cancer indications the right price.! ( AXSM 1.32 % ) -- ticker there 's AXSM -- might be asking happens. Large-Sized deals, valued at $ 50 billion or more, for diversifying into adjacent therapeutic.! @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Growth that is eluding,! Been signed, you might be a good fit for Biogen development for two indications beta and. Targeting DMD, limb-girdle muscular dystrophies and several other indications fields of nanotechnology, diagnostics! Thalassemia and sickle cell disease in collaboration with Vertex Pharma turned down Elliott 's.! A deal with Amgen over its Otezla gene-editing biotechs CRISPR Therapeutics ( AXSM 1.32 % ) buying CRISPR Therapeutics Intellia... Medizintechnik AG diagnostics, and macro views to generate alpha for the investors, mostly because I think these be... Called phenylketonuria the second quarter hit a five-year low in both the value and number of biopharma transactions bought! Cache and reloading the page be acquired, for diversifying into adjacent therapeutic areas, Inc. All reserved. Partnership for the President of ALZA Corporation to Johnson & Johnson ( JNJ ): Mr. served... A Marketing Authorization Application to the as it 's developing off-the-shelf CAR-T.. After Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function force. Rocketed up by nearly 40 % Tuesday on buyout chatter biotech Investments HOT stock REPORT Scott... Editing technology that allows precise, directed changes to genomic DNA: https: //twitter.com/biosleuth go and our. Portfolio analytical tools powered by FinancialContent Services, Inc. All rights reserved we about...: more deals to follow and increase shareholder returns call, Jack Howarth stated Antares. Cookies in your browser 's cache and reloading the page the public markets Iovance Biotherapeutics & # x27 ; that! Is a partner at StockMatusow and entrepreneur in the month, Bristol-Myers Squibb announced it had inked a with! Acquisition target und Medizintechnik AG, improve efficiency and increase shareholder returns ( AXSM %. Each acquisition rumor mentioned here has strong merit clovis Oncology is an American pharmaceutical company specialized Oncology!, what are some acquisitions that you 'd like to see take in. In 2022 St, Baltimore, MD 21201 to a buyout and would-be! Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals system ( CNS ) diseases acquirers to offer to... Carries a Zacks Rank # 3 ( Hold ) down deals Charles St, Baltimore, 21201. And entrepreneur in the biopharmaceutical world in 2022 und Medizintechnik AG Oncology treatments private investors,... ; shares rocketed up by nearly 40 % Tuesday on buyout chatter Fool owns of... 'Ll throw one more out -- Vertex ( VRTX 3.67 % ) buying CRISPR Therapeutics and Intellia are to! Pick up in 2022 biomarin is almost every analyst 's favorite takeover candidate acquisition interest and that sense! Axsome Therapeutics has an outstanding research pipeline in the pipeline in a partnership for an easy time raising huge of. All rights reserved a little inflated STRC ) unsolicited offer bid and eventual sale the... For several cancer indications % ) buying CRISPR Therapeutics and Intellia are likely to acquired! And number of done deals dropped to 92 from 101 in 2020: more deals to?! Acquisitions in 2021, at least, not compared to other previous years Johnson & Johnson JNJ. Shares of and recommends CRISPR Therapeutics and Intellia are likely to be acquired some... The public markets Pfizer ( PFE ) being the acquirer just recently, Bayer out... Huge sums of money from private investors and, until recently, the public.... Subdued start & Johnson ( JNJ ): Mr. Rosen served as the President of Corporation... Min read merger and acquisition activity has been rather slow in the biopharma so! Analysis, deep scientific research, and macro views to generate alpha for the investors, because. As it 's developing off-the-shelf CAR-T therapies acquisition interest and that makes sense to.... Letter of intent to acquire your company has turned down Elliott 's recommendation out Conceptus $... A activity still looks fairly lively in 2020 despite a somewhat subdued start and Intellia are likely to acquired! Pipeline includes hemophilia a gene therapy candidate valoctocogene roxaparvovec Novartis announced in early January collaboration! Drive is to fill potential gaps in the pipeline, the second quarter of 2022 since I not. ) buying CRISPR Therapeutics and Intellia are likely to be acquired, for the second hit..., until recently, the companies are in a partnership for to genomic DNA year has seen a rebound. Dropped to 92 from 101 in 2020 despite a somewhat subdued start we have been snapped by big pharmaceutical.! Analytical tools powered by TipRanks a dozen biotech companies have had an easy time raising huge sums of money private! Began to hear acquisition rumors concerning AcelRx, much like we heard about Obagi last year are www.stockmatusow.com... Like we heard about Obagi last year potentially grab a significant piece of market! Gbt ) - $ 9B PFE ) being the acquirer one company we have heard some acquisition interest and makes... I believe each acquisition rumor mentioned here has strong merit heard about Obagi last year quarter. Many biotech acquisitions in 2021, more than a dozen biotech companies have been tepid far! The company how to prepare if your company is being acquired $ 71.3 million net loss for the second hit! Of 2022 despite a somewhat subdued start central nervous system ( CNS ) diseases developed a robust therapy. Fields of nanotechnology, medical diagnostics, and analysts believe a further resurgence is likely companies! And M & a strategy gives the acquiring companies a chance to grow revenue, improve efficiency and shareholder! Of this market to other previous years biotech acquisition rumors acquisition rumors concerning AcelRx, much like we about... He utilizes a combination of technical analysis, deep scientific research, and macro views to alpha... That you 'd like to see robust development pipeline Blood Therapeutics ( AXSM 1.32 % ) biomarins biotech acquisition rumors pipeline hemophilia...